胰高血糖素样肽-1受体激动剂治疗多囊卵巢综合征的研究进展  

Glucagon like peptide-1 receptor agonist in the treatment of polycystic ovary syndrome

作　　者：乔冠华[1] 李强[1] Qiao Guanhua Li Qiang.(Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China)

机构地区：[1]哈尔滨医科大学附属第二医院内分泌代谢病科,150086

出　　处：《国际内分泌代谢杂志》2017年第3期181-185,共5页International Journal of Endocrinology and Metabolism

基　　金：国家自然科学基金资助项目（81170744,813709027）

摘　　要：多囊卵巢综合征（PCOS）是育龄期女性常见的一类内分泌紊乱疾病,可导致不孕.目前其病因尚未完全明确.高雄激素血症、胰岛素抵抗（IR）及高胰岛素血症等内分泌激素紊乱是其重要特征.现已证实,胰高血糖素样肽-1受体激动剂（GLP-1Ra）能够改善PCOS患者IR,减轻体重,并能影响其睾酮、黄体生成素、卵泡刺激素的分泌,因而可能干预PCOS的发生、发展.与此同时,GLP-1 Ra还能对PCOS伴发2型糖尿病、心血管系统疾病、非酒精性脂肪性肝病发挥作用.Polycystic ovary syndrome （PCOS） is one of the common endocrine disorders in reproductive-aged women,which is associated with a serious consequence to infertility.The etiology is not yet clear at present.Hyperandrogenism,insulin resistance （IR） and hyperinsulinemia and other endocrine hormone disorders are the most important characteristics.It has been showed that glucagon-like peptide-1 receptor agonist （GLP-1Ra） can improve IR,lose weight,and have effects on the secretion of testosterone,luteinizing hormone and follicle stimulating hormone,and thus likely to make it possible that GLP-1Ra be used to interfere with the occurrence and development of PCOS.At the same time,GLP-1Ra can also play a role in the development of PCOS associated with type 2 diabetes,cardiovascular disease,and nonalcoholic fatty liver disease.

关 键 词：多囊卵巢综合征 胰高血糖素样肽-1受体激动剂 胰岛素抵抗 体重 性激素 

分 类 号：R711.75[医药卫生—妇产科学]